Alnylam's CEO Dr. Yvonne Greenstreet discusses HELIOS-B at the European Society of Cardiology Congress in London

blonca9
Aug 31, 2024
1 min read

Dr. Greenstreet shares her opinion of why she believes the data places vutrisiran in a competitive position to be a first line choice for ATTR-CM, and clarifies market confusion around a data point that was presented yesterday.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

Alnylam's CEO Dr. Yvonne Greenstreet discusses HELIOS-B at the European Society of Cardiology Congress in London

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight